Bod Australia will launch what is believed to be the first CBG isolate into the Australian market this month as an observational study revealed its positive effect as an anti-inflammatory.

The 25ml oil, which is manufactured in Switzerland, is due to land in Australia later this week or next and will be made available through the Special Access Scheme medicine soon after.

Bod flagged the launch back in May, and will finally begin distribution over the next few weeks.

The observational study found CBG helped alleviate a number of fibromyalgia symptoms

It will launch under the MediCabilis brand.

The arrival of the CBG isolate, which is not psychoactive, follows an observational study in the UK which demonstrated encouraging results for its use in treating inflammation-based conditions.

Patients showed improvements across various symptoms associated with fibromyalgia and irritable bowel syndrome with the greatest improvement seen in those who were taking CBG for longer.

Bod head of sales and marketing Michael Tesoriero described minor cannabinoids as “an exciting and emerging area”.

The company is also exploring the mildly psychoactive cannabinoid CBN which, like CBG, is thought to have anti-inflammatory value in addition to possessing antibiotic and anticonvulsant benefits.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...

Leave a comment